Bovine herpesvirus cDNA and Antigen

Bovine herpesvirus (BHV) is a group of viruses that cause diseases in cattle. There are several types of BHV, including BHV-1, BHV-2, BHV-5, and BHV-8, which can cause different symptoms in cattle. BHV-1, also known as bovine viral diarrhea virus (BVDV), can cause respiratory and enteric symptoms, decreased weight gain, decreased milk production, and decreased fertility. BHV-2, also known as bovine herpes mammillitis virus (BHMV), can cause skin lesions and mastitis. BHV-5 and BHV-8 have been associated with respiratory disease in cattle. BHV infections can be prevented by vaccination and biosecurity measures, and control of outbreaks can be achieved through culling of infected animals.

Bovine herpesvirus (BHV) antigen refers to a substance that is recognized by the immune system as foreign and triggers the production of antibodies. This antigen is found in the BHV virus and can be used in laboratory tests to detect BHV infections in cattle. Detection of BHV antigen in blood or serum samples can help diagnose BHV infections and monitor the effectiveness of vaccines against the virus. Different BHV antigens may be used to detect different types of BHV, such as BHV-1, BHV-2, BHV-5, and BHV-8.

The genome of Bovine herpesvirus (BHV) is the complete genetic material of the virus. It is composed of double-stranded DNA (deoxyribonucleic acid) and is approximately 170 kilobases in length. The BHV genome encodes for several proteins that are involved in virus replication, assembly, and pathogenesis. Understanding the BHV genome can help in the development of diagnostic tools and vaccines for the control of BHV infections in cattle. The genome can also be used to study the genetic diversity and evolution of BHV in different cattle populations. Different types of BHV, such as BHV-1, BHV-2, BHV-5, and BHV-8, have distinct genomes.

The virus encodes several glycoproteins that are important for viral entry, replication, and immune evasion, including:

Glycoprotein gC: This protein is a component of the viral envelope and is involved in binding to heparan sulfate on the host cell surface.

Envelope glycoprotein B: This protein is also a component of the viral envelope and is involved in fusion of the viral envelope with the host cell membrane.

Envelope glycoprotein H: This protein is a component of the viral envelope and is involved in fusion of the viral envelope with the host cell membrane.

VP22: This protein is a tegument protein that is involved in viral replication and assembly.

Envelope glycoprotein D: This protein is a component of the viral envelope and is involved in binding to receptors on the host cell surface.

Envelope glycoprotein E: This protein is a component of the viral envelope and is involved in fusion of the viral envelope with the host cell membrane.

Envelope glycoprotein I: This protein is a component of the viral envelope and is involved in binding to receptors on the host cell surface.

These viral proteins play important roles in the viral life cycle and pathogenesis of bovine herpesvirus and are potential targets for antiviral therapy and vaccine development.

Bovine herpesvirus (BHV) cDNA and recombinant antigens have been used to develop a variety of applications that have the potential to benefit bovine health. These applications include diagnosis, vaccine production, and the development of antiviral therapies.
Diagnosis: BHV cDNA and recombinant antigens can be used to diagnose BHV infections in cattle. Diagnosis is important for the early detection and prevention of BHV-associated diseases. The cDNA and antigens can be used to detect the presence of BHV in blood or other samples taken from infected animals.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.